Patents by Inventor Mahmood Ahmed

Mahmood Ahmed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230064920
    Abstract: The present application provides new processes for preparing arachidonoylethanolamine analogues. Intermediates useful for preparing the compounds are also provided.
    Type: Application
    Filed: November 20, 2020
    Publication date: March 2, 2023
    Applicant: TRAVECTA THERAPEUTICS PTE. LTD.
    Inventors: Mahmood AHMED, Sing Yeung Frankie MAK, Ravi Kumar PUTHUKANOORI, Sampath Kumar NANGUNOORI, Ramana Murthy Venkata APPALA, Narendar VENNU, Filippo ROMOLI, Giovanni MARRAS
  • Publication number: 20220112225
    Abstract: The present application provides anandamide and 2-arachidonoyl glycerol compounds useful for treating a disease or disorder in a subject in need thereof. Pharmaceutical compositions comprising the compounds and methods of treating diseases or disorders are also provided.
    Type: Application
    Filed: January 10, 2020
    Publication date: April 14, 2022
    Inventors: David Lawrence Silver, Mahmood Ahmed, Sing Yeung Frankie Mak
  • Publication number: 20220033608
    Abstract: The invention relates to an expandable bead comprising a) a polyolefin selected from polyethylene (PE), polypropylene (PP) and mixtures thereof and b) thermoplastic microspheres encapsulating a blowing agent.
    Type: Application
    Filed: November 20, 2019
    Publication date: February 3, 2022
    Inventors: James Arthur AUGER, Syed Mahmood AHMED, Abdul Rahim Ahamed ARAFATH, Ali Khalid AL-KHORAYEF
  • Publication number: 20180236714
    Abstract: The disclosure describes systems and methods for performing additive manufacturing. The method includes forming a first layer of a product on a target surface, heating a portion of the first layer with a directed energy source, and forming a second layer of the product on the first layer. The system for performing additive manufacturing includes a vacuum chamber, a target surface disposed in the vacuum chamber, a first layer of material formed on the target surface, a directed energy source configured to heat a portion of the first layer, and a second layer of material formed on the heated portion of the first layer.
    Type: Application
    Filed: August 25, 2016
    Publication date: August 23, 2018
    Inventors: Abdul Salam THELAKKADAN, Tariq SYED, Syed Mahmood AHMED, Abdullah Shamroukh OTAIBI-AL
  • Patent number: 9556201
    Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: January 31, 2017
    Assignee: GLAXOSMITHKLINE LLC
    Inventors: Pui Yee Ng, Charles Blum, Lauren McPherson, Robert B. Perni, Chi B. Vu, Mohammed Mahmood Ahmed, Jeremy S. Disch
  • Patent number: 8324254
    Abstract: The present invention provides compounds of formula (I) or salts thereof: having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders mediated by S1P1 receptors.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: December 4, 2012
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, Gerard Martin Paul Giblin, James Myatt, David Norton, Dean Andrew Rivers
  • Publication number: 20120252780
    Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    Type: Application
    Filed: October 29, 2010
    Publication date: October 4, 2012
    Inventors: Pui Yee Ng, Charles Blum, Lauren McPherson, Robert B. Perni, Chi B. Vu, Mohammed Mahmood Ahmed, Jeremy S. Disch
  • Patent number: 8236947
    Abstract: Disclosed are quinoline compounds having affinity for the 5-HT6 receptor and having the formula: where R1, R2, R3, R4, R5, n, m, p and A are defined herein, and salts thereof, compositions containing these compounds and salts and processes for making and using the same.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: August 7, 2012
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, Christopher Norbert Johnson, Martin C Jones, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, Charles Edward Wade, David R Witty
  • Patent number: 8101775
    Abstract: The invention relates to compounds of formula (I) wherein one of R5 and R6 is hydrogen or R2 and the other is (a) pharmaceutical compositions containing them and their use in the treatment of conditions or disorders which are mediated via the S1P1 receptor.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: January 24, 2012
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, James Myatt, David Norton, Dean Andrew Rivers
  • Publication number: 20110237792
    Abstract: Disclosed are quinoline compounds having affinity for the 5-HT6 receptor and having the formula: where R1, R2, R3, R4, R5, n, m, p and A are defined herein, and salts thereof, compositions containing these compounds and salts and processes for making and using the same.
    Type: Application
    Filed: June 3, 2011
    Publication date: September 29, 2011
    Inventors: Mahmood AHMED, Christopher Norbert Johnson, Martin C. Johnes, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, Charles Edward Wade, David R. Witty
  • Patent number: 7977337
    Abstract: Disclosed are quinoline compounds having affinity for the 5-HT6 receptor and having the formula: where R1, R2, R3, R4, R5, n, m, p and A are defined herein, and salts thereof, compositions containing these compounds and salts and processes for making and using the same.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: July 12, 2011
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, Christopher Norbert Johnson, Martin C Jones, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, Charles Edward Wade, David R Witty
  • Publication number: 20100305107
    Abstract: Disclosed are quinoline compounds having affinity for the 5-HT6 receptor and having the formula: where R1, R2, R3, R4, R5, n, m, p and A are defined herein, and salts thereof, compositions containing these compounds and salts and processes for making and using the same.
    Type: Application
    Filed: July 30, 2010
    Publication date: December 2, 2010
    Inventors: Mahmood AHMED, Christopher Norbert Johnson, Martin C. Jones, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, Charles Edward Wade, David R. Witty
  • Patent number: 7799774
    Abstract: Disclosed are quinoline compounds having affinity for the 5-HT6 receptor and having the formula: where R1, R2, R3, R4, R5, n, m, p and A are defined herein, and salts thereof, compositions containing these compounds and salts and processes for making and using the same.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: September 21, 2010
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, Christopher Norbert Johnson, Martin C Jones, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, Charles Edward Wade, David R Witty
  • Publication number: 20100113528
    Abstract: The present invention provides compounds of formula (I) or salts thereof: having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders mediated by S1P1 receptors.
    Type: Application
    Filed: April 17, 2008
    Publication date: May 6, 2010
    Inventors: Mahmood Ahmed, Gerard Martin Paul Giblin, James Myatt, David Norton, Dean Andrew Rivers
  • Publication number: 20100113796
    Abstract: The invention relates to compounds of formula (I) wherein one of R5 and R6 is hydrogen or R2 and the other is (a) pharmaceutical compositions containing them and their use in the treatment of conditions or disorders which are mediated via the S1P1 receptor.
    Type: Application
    Filed: December 19, 2007
    Publication date: May 6, 2010
    Inventor: Mahmood AHMED
  • Publication number: 20100048639
    Abstract: The present invention relates to novel oxadiazole compounds of formula (I) having pharmacological activity, pharmaceutical compositions containing them and their use in the treatment of various disorders.
    Type: Application
    Filed: December 19, 2007
    Publication date: February 25, 2010
    Applicant: GLAXO GROUP LIMITED
    Inventors: Mahmood Ahmed, James Myatt, David Norton, Dean Andrew Rivers
  • Publication number: 20090298841
    Abstract: The present invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
    Type: Application
    Filed: August 14, 2009
    Publication date: December 3, 2009
    Inventors: Mahmood Ahmed, Christopher Norbert Johnson, Martin C. Jones, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, Charles Edward Wade, David R. Witty
  • Patent number: 7603473
    Abstract: Example embodiments allow a local network client to access information about a shared gateway to determine its actual amount of bandwidth consumption. The client can also obtain the total capacity of such shared gateway. Using its knowledge of its own bandwidth consumption, it can determine the other local network clients' usage of the shared gateway. With all of this information, i.e., total capacity of the shared gateway, the actual usage of the shared gateway, and the usage by other clients within the local network, the client can adjust or throttle background file transfers in order to keep the actual data transfers across the shared gateway within a reasonable percentage of the total capacity available. That is, a client will give priority to other local network computing machines' usage of the shared gateway by adjusting data transfers for its own background transfer system based on usage across a shared gateway.
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: October 13, 2009
    Assignee: Microsoft Corporation
    Inventors: Anna Magdalena Hester, Barbara Harder, Edward Francis Reus, Kancheng Cao, Mahmood Ahmed Dhalla, Mike Zoran, Narayana Mahankali, Jeffrey S. Roberts
  • Patent number: 7601837
    Abstract: The present invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: October 13, 2009
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, Christopher Norbert Johnson, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, David R Witty
  • Publication number: 20090036682
    Abstract: The present invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
    Type: Application
    Filed: September 5, 2008
    Publication date: February 5, 2009
    Inventors: Mahmood AHMED, Christopher Norbert Johnson, Martin C. Jones, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, Charles Edward Wade, David R. Witty